Sniff your shot? new nasal COVID vaccine enters testing
NCT ID NCT05736835
Summary
This study is testing a new COVID-19 vaccine given as a single spray into the nose. Researchers want to see if it is safe and if it triggers a good immune response against the virus. The trial will include up to 400 healthy adults aged 18 to 80, some of whom have had prior COVID shots or infection. Participants will be followed for six months after receiving the nasal spray.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Velocity Clinical Research
San Diego, California, 91942, United States
-
Velocity Clinical Research
Boise, Idaho, 83642, United States
-
Velocity Clinical Research
Sioux City, Iowa, 51106, United States
-
Velocity Clinical Research
Rockville, Maryland, 20854, United States
-
Velocity Clinical Research
Omaha, Nebraska, 68134, United States
-
Velocity Clinical Research
Vestal, New York, 13850, United States
-
Velocity Clinical Research
Providence, Rhode Island, 02818, United States
-
Velocity Clinical Research
Cedar Park, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.